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Summary
Chronic active Epstein–Barr virus (CAEBV) disease is a rare condition characterised
by persistent EBV infection in previously healthy individuals. Defective EBV gen-
omes were found in East Asian patients with CAEBV. In the present study, we
sequenced 14 blood EBV samples from three UK patients with CAEBV, comparing
the results with saliva CAEBV samples and other conditions. We observed EBV
deletions in blood, some of which may disrupt viral replication, but not saliva in
CAEBV. Deletions were lost overtime after successful treatment. These findings are
compatible with CAEBV being associated with the evolution and persistence of
EBV+ haematological clones that are lost on successful treatment.
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Epstein–Barr virus (EBV) infects >95% of the population
worldwide.1 A small number of patients develop life-
threatening persistence of high-level EBV replication follow-
ing an infectious mononucleosis syndrome, often associated
with splenomegaly and hepatitis.2 Chronic active EBV
(CAEBV) disease is characterised by infiltration of tissues by
EBV+ T, natural killer (NK) or less frequently B cells and can
progress into lymphoproliferative disease. Clonal expansion
of EBV-infected T or NK cells is well described.3
To date, CAEBV has been mostly described in Asian or
South/Central American patients.4 Frequent deletions in
the EBV genome have been found in samples from Japa-
nese CAEBV patients (35%) and other EBV-driven neo-
plasms.5–7 However, it is unclear if these deletions are
specific for Asian EBV strains, whether they are present in
viral genomes in different sites and how they evolve over-
time.
In the present study, we sequenced EBV from serial blood
samples obtained from three UK patients with CAEBV dis-
ease. The results were compared with sequences from saliva
of patients with CAEBV and blood and tissue from other
benign and malignant EBV-related conditions.
Methods
Patients
A total of 14 blood samples from three patients with
CAEBV from Great Ormond Street Hospital (GOSH) were
sequenced. The patients presented with a high EBV viral load
(Fig 1A) and EBV-driven haemophagocytic lymphohistiocy-
tosis (HLH). Primary and secondary immunodeficiency was
excluded and a diagnosis of CAEBV was considered (Data
S1). All patients were treated with rituximab and followed
the HLH-94 protocol. As no response to treatment was seen
for patients 1 and 3, EBV cell subsets was done and revealed
EBV in T cells rather than B cells. They both underwent
peripheral blood stem cell transplants (PBSCTs). Despite
ongoing EBV viraemia, patient 2 did not receive a transplant
because no further flares of HLH were observed after treat-
ment. Viraemia lasted for >3 years and subsequent blood test
revealed EBV in both B and T cells.
Study design
The data were compared with 67 EBV sequences from
asymptomatic (saliva, healthy-S), infectious mononucleosis
Fig 1. (A) Viraemia and treatment in a Great Ormond Street Hospital (GOSH) patient with chronic active Epstein–Barr virus (CAEBV). Black
line represents viraemia over a period of 500 days after the first hospital record. Red lines: rituximab doses, blue lines: peripheral blood stem cell
transplant (PBSCT), filled black triangle: deep-sequencing samples, empty black squares: sequences samples that did not pass quality control.
Patient 1 had a total of seven samples sequenced successfully of which four preceded starting treatment, one during rituximab treatment (time-
point 5), one after four doses of rituximab (time-point 6) and the last one after PBSCT when the patient had EBV reactivation, but no symptoms
(time-point 7). Patient 2 had a deep-sequencing sample taken before treatment and one after four doses of rituximab, to which they responded
clinically despite the persistence of viraemia. Patient 3 had two previous episodes of EBV-driven haemophagocytic lymphohistiocytosis (HLH)
that spontaneously resolved. During the third episode, the patient started treatment with rituximab and two samples were collected during the
first four doses (time-point 1 and 2), two samples after PBSCT (time-point 3 and 4) and a last sample after the last dose of rituximab (time-
point 5). The patient had EBV reactivation at low levels, with no sign of HLH. (B) Summary of deletions (≥30 bp) that were identified in EBV
genomes. Each grey line represents an EBV genome from a single patient (if longitudinal samples from one patient were available, only one sam-
ple pre-transplant and with the highest read depth was included). Only samples with deletions were visualised here. Colours indicate groups: yel-
low for salivary healthy samples (healthy-S), orange for blood infectious mononucleosis (IM-B), green for salivary CAEBV (CAEBV-S), light blue
for blood CAEBV (CAEBV-B), dark blue for blood primary immunodeficiency (PID-B), red for EBV-positive solid organ transplant (SOT-B),
purple for blood post-transfusion lymphoproliferative disease (PTLD-B), pink for tumour PTLD (PTLD-T) and grey for tumour from Hodgkin
lymphoma (HL-T). The purple histograms indicate the frequency of deletions (as number of samples) in each genomic region. The location of
the main components of EBV genome are also shown based on GenBank sequence NC-007605.1. (C) EBV components deleted in CAEBV and
other malignancies. The horizontal lines represent deletions [using the same colour coded in (B)]. The location of EBV genes and components is
shown based on NC-007605.1. The number on top of each microRNA (miRNA) indicates its miRNA ID (three for example corresponds to ebv-
mir-BART3). The red cross represents the nonsense variant (Glu22*, GAG?TAG at position 130 684 bp) identified in CAEBV samples in BXLF2
or glycoprotein H (gp85). (D) Summary of deleted components in longitudinal blood samples in patients with CAEBV. The x-axis represents dif-
ferent time-points of sampling [corresponding to number in (A)]. Both larger deletions (containing IR1 and late lytic genes and BART mRNAs)
and the missense variant in BXLF2 are shown. The arrows indicate treatment, red for rituximab and blue for PBSCT. Transparency indicates the
frequency (%) of viral genomes with the deletion. [Colour figure can be viewed at wileyonlinelibrary.com]
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(blood, IM-B), and other patients with CAEBV [a blood and
a saliva sample from a CAEBV patient from GOSH and sal-
iva samples from a paediatric USA CAEBV cohort, referred
further as CAEBV-B (blood) and CAEBV-S (saliva)], a blood
sample from a patient with primary immunodeficiency disor-
der (PID-B), post-transfusion lymphoproliferative disease (in
blood, PTLD-B, and in tumour, PTLD-T), post-solid organ
transplant viraemia (in blood SOT-B) and Hodgkin lym-
phomas (tumour, HL-T) (Table SI).
Statistical and sequence analysis
Samples were sequenced and analysed using a standard pipe-
line and in-house R scripts (Supplementary Methods; Fig-
ure S1). The methods for diversity calculations and
haplotype reconstruction have been described elsewhere.8,9
Results and discussion
EBV genomes in blood and saliva from CAEBV patients
The EBV blood genomes from patients with CAEBV clus-
tered with European/USA sequences; longitudinal samples,
including those after PBSCT, clustered by patient (Fig-
ure S2). Within-host CAEBV nucleotide diversity (p) was
low and comparable to other EBV blood samples (Table SI,
Figures S3 and S4). In contrast, CAEBV salivary samples
showed significantly higher EBV diversity compared to blood
and tumour samples (P < 0001), indicating the presence of
multiple strains (Figures S5–S7). Single nucleotide variants
(SNVs) and small (<2 kbp) deletions were present in all
specimens, including samples from healthy-S and IM-B. The
SNVs and deletions were largely located in latent genes [e.g.
Table I. Patients’ descriptions and clinical details.
Pat
Age,
years Sex Description Treatment Transplant Reactivation
N
samples









4 months post PBSCT
had reactivation of EBV








4 doses of rituximab
The patient did not proceed
to BMT as she responded
well to HLH treatment and




positive for 35 years
without symptoms
2





Over the following 6 months
she had two further EBV-
related HLH relapses treated
with steroids. Although her
HLH associated symptoms
rapidly responded, her EBV
viraemia continued to rise
During the third HLH relapse









4 doses of rituximab
with successfully
depleted B cells but not
reduced EBV viral load
(pre-transplant)
After third HLH relapse
was commenced on




reduction in EBV viral
load






resolved after 1 dose of
rituximab
5
BMT, bone marrow transplantation; CMV, cytomegalovirus; DC, direct current; EBV, Epstein–Barr virus; HLH, haemophagocytic lymphohistio-
cytosis; MSD, matched sibling donor; MUD, matched unrelated donor; PBSCT, peripheral blood stem cell transplant; PCR, polymerase chain
reaction; PTLD, post-transfusion lymphoproliferative disease.
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Epstein–Barr nuclear antigen 3 (EBNA3), latent membrane
protein 1/2 (LMP1/2)], EBV large tegument protein 1
(BPLF1) and EBV envelope glycoprotein GP350 (BLLF1)
(Figures S8–S16). Our results showed EBV shed in saliva has
the hallmarks of lytic replication and frequent mixed infec-
tions consistent with previous studies.10
Larger deletions
We identified low frequency (<50% within-host viral gen-
omes) larger (>2 kb) EBV deletion in CAEBV patient 1 (one
of four) (128 013–139 461 bp), as well as PTLD (two of
four) and HL (two of seven) tumour-tissue at position
120 470–158 062 (Fig 1B; Figure S17). This includes the
Bam-HI A rightward transcript (BART) microRNA (miRNA)
clusters, several lytic genes, including scaffold proteins (e.g.
BdRF1, BVRF2), glycoproteins (e.g. BXLF2), a tegument pro-
tein (BVRF1), and regulators of late gene transcription
(BcRF1, BVLF1). Interestingly, patient 1 also had a nonsense
variant in BXLF2 (>50% frequency, Fig 1C). A second larger
deletion at positions 12 118–15 159, overlapping the major
EBV repeat (IR1), was present in blood from CAEBV (four
of four) and PID patients (Fig 1B). This deletion overlaps
with a smaller deletion found in a PTLD tumour (one of
four) at 11 494–12 322 bp.
EBV variation overtime in patients with CAEBV
Analysis of variation over time revealed that the blood from
CAEBV patient 1 with EBV present predominantly in T cells,
showed higher genomic heterogeneity with increasing num-
ber of low frequency (<50%) variants and deletions com-
pared to other patients (Fig 1D; Figures S18–S20). Deletions,
the BXLF2 nonsense variant and other non-synonymous
SNVs overall persisted after rituximab treatment (Fig 1D).
Clinical deterioration necessitated PBSCT (Table I), following
which SNVs and deletions were absent from the virus reacti-
vating asymptomatically.
In contrast, patient 2 had fewer non-synonymous SNVs
and deletions with a picture like the blood from patients
with PTLD with evidence of clonality. The deletion in IR1
was lost after rituximab (Fig 1D).
The CAEBV patient 3, who also failed to respond to ritux-
imab, had several SNVs and showed the deletion in IR1. The
deletion was not immediately lost after PBSCT (27 days
after), but it disappeared afterwards (62, 69 days after), even
though viraemia was still present (Fig 1A).
Discussion
The pathogenesis of CAEBV disease is not completely under-
stood. In healthy people, EBV is latent in B cells, whereas in
many patients’ clinical features of CAEBV are associated with
the detection in T or NK lymphocytes, particularly in East
Asia.4 It is unclear how EBV enters T and NK cells as they
do not express the EBV complement receptor 2 (CR2 also
known as CD21).
In the present study, we show that EBV deletions are pre-
sent in all sequences, even from healthy individuals. These
deletions, as well as SNVs, are found in latent genes and in a
few lytic genes (e.g. BPLF1 and BLLF1), which are known to
be under positive selection.11,12
In addition, we found that blood, but not the saliva, of
patients with CAEBV contained defective viral genomes,
affecting BART miRNAs and late lytic genes (128 013–
139 461 bp). Overlapping this region, we also identified
one nonsense mutation in CAEBV samples affecting the
glycoprotein H (BXLF2). Similar deletions are also found
in malignancies, including tumours from PTLD and HL
and extra-nodal NK/T cells lymphoma and EBV+ diffuse
large B-cell lymphoma.5 Data from mouse models suggest
that loss of the BART miRNAs may drive a more lytic
phenotype and faster cell growth, predisposing to tumour
formation.7,13 Although, the mechanism is not entirely
clear, the abortive EBV replication resulting from the
absence of these regions may prevent normal cell death
associated with lytic replication.7,14 The cells remain
exposed to continued high expression of lytic genes, driven
by immediate early promotors, BZLF1 and BRLF1, which
always remain intact. However, only one patient with
CAEBV in this study (and 35% Japanese patients5) have
deletions in this area and the others did not show any
specific nonsense/missense variants, so further work is
needed to determine the role of deletions in the CAEBV
disease pathogenesis.
We also identified a 3k deletion at the 50 of the EBV gen-
ome (12 118–15 159 bp) in samples from patients with
CAEBV and PID. The deletion overlapped with the EBV
internal repeat (IR1) region and will require further confir-
mation using long-read sequencing. However, it overlaps
with a smaller deletion (828 bp) found in the tumour of a
patient with PTLD. This area includes BWRF1 and Wp,
whereas the PTLD deletion affects the Cp. The identified
deletions overlap with deletions found in Japanese CAEBV,
diffuse large B cell and extra-nodal NK/T cell lymphoma.5
Further tests in vitro showed that a deletion of Cp resulted
in a higher rate of B-cell growth transformation.15
Although similar EBV deletions have previously been
described in CAEBV infection and malignancies,5–7 most
were in patients of Asian origin. In the present study, we
show that defective genomes occur independently of sample
and patient geographical origin and are not necessarily asso-
ciated with strains predominantly circulating in Asian coun-
tries or from patients of Asian origin.
Persistence of larger deletions in longitudinally sampled
blood has been associated with clonal expansion of the cells
in which they are found.7 Importantly, we show that clinical
response to therapy is associated with loss of deletions and
nonsense variants in virus recovered after treatment. The
short-term persistence following PBSCT of the deletion in
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patient 3’s EBV may reflect a longer half-life of the lympho-
cyte clone in which it was located.
Our present findings of low-level potentially premalignant
clones together with evidence of replicating virus in blood
from patients with CAEBV fits with the hypothesis that dele-
tions occur only when a particular subset of the patient’s
blood cells are infected with EBV. Progenitor lymphoid cells,
which overtime differentiate into B, T, or NK cells, have been
suggested to be the target cell type.14 Rituximab and/or
PBSCT may remove the clone and when the same virus reac-
tivates after treatment, we found it no longer contained the
defective genomes.
In conclusion, our present study showed that clones con-
taining EBV genomes with specific large deletions are found in
blood but not saliva from European patients with CAEBV.
While rituximab reduced the burden of EBV deletions in some
cases, it had no impact on the prevalence of EBV deletions in
T/NK-cell associated CAEBV. The absence of these EBV-
deletions from virus reactivating following PBSCT suggests the
loss of the clone. The possibility that these deletions could be
useful biomarkers for monitoring the success of treatments for
CAEBV now needs to be investigated in larger studies.
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Data S1.
Fig S1. Boxplot showing the average depth, excluding
duplicate reads and repeated regions, for each sample
coloured by clinical group.
Fig S2. MDS clustering of all samples coloured by patient
group. Multiple samples from chronic active Epstein–Barr
virus (CAEBV) patients P1, P2, P3 and the paired blood-sal-
iva (P4) are indicated.
Fig S3. The y-axis shows the within host nucleotide diver-
sity (p) per sample by group (x-axis and colours). Vertical
grey dashed line shows lower and upper quartile, and the
grey dot is the median.
Fig S4. Relationship between average depth (x-axis) and
diversity calculation (y-axis). Higher diversity is not associ-
ated with higher depth (minimum depth shown is 910; see
also Table SI).
Fig S5. Frequency distribution of variants (obtained by
mapping against their own consensus) for (A) blood SOT
samples suspected as harbouring mixed infections (B) all sali-
vary chronic active Epstein–Barr virus (CAEBV) samples and
(C) saliva from an asymptomatic shedder.
Fig S6. Haplotype frequency after haplotype reconstruc-
tion (HaROLD)8,9 in SOT blood samples (A), saliva samples
from patients with chronic active Epstein–Barr virus
(CAEBV) (B) and asymptomatic shedder (C). The majority
haplotype is coloured pink by convention with additional
haplotypes coloured green and yellow.
Fig S7. Multidimensional scaling (MDS) clustering includ-
ing all EBV sequences included in the paper (in grey) and
the reconstructed haplotypes sequences.
Fig S8. Relationship between number of SNVs in total (in-
cluding all types of coding and non-coding mutations with
at least 2% frequency and strict QC as explained in the
‘Methods’ section) and the average depth by sample coloured
by disease group (minimum average depth is 910).
Fig S9. Boxplots for number of single nucleotide variants
(SNVs) in each EBV-related disease/group. Significance:
*P ≤ 005, **P ≤ 001.
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Fig S10. Location of single nucleotide variants (SNVs),
excluding samples with possible mixed infections in the EBV
genome.
Fig S11. The most common non-synonymous mutations
are coloured by disease group.
Fig S12. Total number of non-synonymous single nucleo-
tide variants (SNVs) by sample (only samples with non-syn-
onymous variants are shown) and genes involved by
category. The size of the filled circles represents the number
of variants.
Fig S13. Size of deletions in all samples, coloured by
group. First plot (at the top) shows the full range of dele-
tion’ sizes (1–24 474). The second plot is a zoom for dele-
tions with sizes between 1 and 100. Indels with a size <30 bp
were present in all groups and considered artefacts.
Fig S14. Distribution of size of deletions (left, all dele-
tions; right, a zoom of sizes from 30 to 10 kbp). Most (95%)
deletions were smaller than 2 kbp, therefore that was chosen
as cut-off to distinguish ‘small’ deletions versus ‘big’ dele-
tions.
Fig S15. Number of triplets (x-axis) versus number of
non-triplets (y-axis) by gene and coloured by group.
Fig S16. Total number of deletions (≥30 bp and <2 kbp
in size) per sample coloured by clinical group (A) and the
genes affected by deletions (B).
Fig S17. Genes affected by larger deletions (>2 kbp) in
each sample coloured by clinical group.
Fig S18. Analysis of single nucleotide variants (SNVs) in
longitudinal samples in patients with chronic active Epstein–
Barr virus (CAEBV). Samples from three patients are shown
in different colours. The top panel shows the number of all
SNVs for each sample. Genes affected by non-synonymous
variants.
Fig S19. (A) Number of total single nucleotide variants
(SNVs) and genes affected by non-synonymous mutations
for longitudinal blood samples for patients with post-transfu-
sion lymphoproliferative disease (PTLD) and infectious
mononucleosis (IM). (B) Total number of bigger deletions
(>2 kbp) and genes affected by deletions in longitudinal
blood samples for IM. Patients with PTLD did not have any
bigger deletions.
Fig S20. Summary of total number of deletions (A) and
their position in the EBV genome (B) for chronic active
Epstein–Barr virus (CAEBV) patient 4 in whole blood and
saliva.
Fig S21. Summary of total number of deletions (A) and
their position in the EBV genome (B) for the PID-B patient
in whole blood, T cells and saliva.
Fig S22. Single nucleotide variants (SNVs) in whole blood
and T cells in the patient with primary immunodeficiency
disorder-blood (PID-B). The y-axis shows the position in the
EBV genome (NC_007605.1) and the colour the type of
mutation. The transparency indicates the frequency.
Fig S23. Representation of the IR1 deletion in chronic
active Epstein–Barr virus (CAEBV). Representative portion of
the alignment file (bam file) for a blood CAEBV sample to
demonstrate IR1 deletion (represented by red reads and black
lines) compared to an infectious mononucleosis (IM) blood
sample where the deletion is not present (reads in grey).
Table SI. Details for each sample.
References
1. Longnecker RM, Kieff E, Cohen JI. Epstein-Barr virus [Internet]. Wolters
Kluwer Health Adis (ESP); 2013 [cited 2020 Oct 28]. Available from:
https://www.scholars.northwestern.edu/en/publications/epstein-barr-virus
2. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, et al.
Characterization and treatment of chronic active Epstein-Barr virus dis-
ease: a 28-year experience in the United States. Blood. 2011;117:5835–49.
3. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is
this an infectious disease, lymphoproliferative disorder, or immunodefi-
ciency? Rev Med Virol. 2006;16:251–61.
4. Kimura H, Cohen JI. Chronic active Epstein–Barr virus disease. Front
Immunol. 2017;8:1867. https://doi.org/10.3389/fimmu.2017.01867.
5. Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al.
Defective Epstein-Barr virus in chronic active infection and haematological
malignancy. Nat Microbiol. 2019;4:404–13.
6. Peng RJ, Han BW, Cai QQ, Zuo XY, Xia T, Chen JR, et al. Genomic and
transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer
T-cell lymphoma. Leukemia. 2019;33:1451–62.
7. Murata T, Okuno Y, Sato Y, Watanabe T, Kimura H. Oncogenesis of
CAEBV revealed: intragenic deletions in the viral genome and leaky
expression of lytic genes. Rev Med Virol. 2020;30:e2095.
8. Cudini J, Roy S, Houldcroft CJ, Bryant JM, Depledge DP, Tutill H, et al.
Human cytomegalovirus haplotype reconstruction reveals high diversity
due to superinfection and evidence of within-host recombination. Proc
Natl Acad Sci USA. 2019;116:5693–8.
9. Pang J, Venturini C, Tamuri AU, Roy S, Breuer J, Goldstein RA. Haplo-
type assignment of longitudinal viral deep-sequencing data using co-
variation of variant frequencies. bioRxiv. 2020:444877.
10. Kwok H, Chan KW, Chan KH, Chiang AKS. Distribution, persistence and
interchange of Epstein-Barr virus strains among PBMC, plasma and saliva
of primary infection subjects. PLoS One. 2015;10:e0120710.
11. Wegner F, Lassalle F, Depledge DP, Balloux F, Breuer J. Coevolution of
sites under immune selection shapes Epstein–Barr virus population struc-
ture. Mol Biol Evol. 2019;36:2512–21.
12. Palser AL, Grayson NE, White RE, Corton C, Correia S, Ba Abdullah
MM, et al. Genome diversity of Epstein-Barr Virus from multiple tumor
types and normal infection. J Virol. 2015;89:5222–37.
13. Lin X, Tsai M-H, Shumilov A, Poirey R, Bannert H, Middeldorp JM, et al.
The Epstein-Barr virus BART miRNA cluster of the M81 strain modulates
multiple functions in primary B cells. PLOS Pathogens. 2015;11:e1005344.
14. Murata T, Sato Y & Kimura H. Modes of infection and oncogenesis by
the Epstein–Barr virus. Reviews in Medical Virology. 2014;24:242–53.
http://dx.doi.org/10.1002/rmv.1786
15. Mabuchi S, Hijioka F, Watanabe T, Yanagi Y, Okuno Y, Masud HM, et al.
Role of Epstein Barr virus BART miRNA C promoter deletion in diffuse
large B cell lymphoma. Cancers (Basel). 2021;13:561.
Short Report
ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. 7
